Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
AstraZeneca's New Cancer Pill Etcamah Fails Late-Stage Breast Cancer Trial
AstraZeneca’s newly approved oral SERD Etcamah failed to meet its primary endpoint in the Phase 3 SERENA-4 trial for first-line advanced breast cancer.
J&J's Rybrevant Achieves Record Overall Survival in Exon 20 EGFR NSCLC
J&J’s Rybrevant plus chemotherapy demonstrated a record median overall survival of nearly three years in patients with EGFR exon 20 insertion mutant NSCLC.
Pharmazz Sovateltide Granted FDA Orphan Drug Designation for NHIE Care
Pharmazz's sovateltide received FDA Orphan Drug Designation for treating neonatal hypoxic-ischemic encephalopathy (NHIE), a severe brain injury in newborns.
FDA Grants Priority Review to Takeda's Zasocitinib for Plaque Psoriasis
The FDA accepted Takeda’s NDA under Priority Review for zasocitinib (TAK-279) to treat moderate-to-severe plaque psoriasis based on Phase 3 LATITUDE data.
Preclinical Study Shows Psilocybin Prevents Chemo-Induced Nerve Damage
New preclinical research indicates that administering psilocybin before chemotherapy protects nerve fibers and prevents severe peripheral nerve damage.
Novartis Suffers Setback as Myotonic Dystrophy Drug Fails Phase 3 Trial
Novartis announced that its antibody-oligonucleotide conjugate, delpacibart etedesiran, failed to meet primary endpoints in the Phase III HARBOR trial.
Endo Axiom Takes Oral Nanoparticle Insulin Into First-in-Human Trial Run
Endo Axiom has dosed the first healthy volunteers in a Phase Ia clinical trial evaluating a novel oral nanoparticle-encapsulated insulin formulation.
Insilico's AI-Discovered Drug Rentosertib Enters Phase 3 IPF Trial Study
Insilico Medicine doses the first patient in a Phase III trial for rentosertib, marking a milestone for AI-discovered therapies in pulmonary fibrosis.
FDA Approves Pharming’s Joenja for Pediatric APDS Immunodeficiency Care
The FDA approved Pharming’s Joenja (leniolisib) as the first oral treatment for children aged 4 to 11 with activated PI3K delta syndrome, a rare disease.
Solstice Oncology Secures $225M to Advance Porustobart in Colon Cancer
Solstice Oncology raised $225 million in Series A funding to advance porustobart, a novel CTLA-4 antibody for treating microsatellite-stable colon cancer.
Novartis Shareholder Urges Board Shake-Up Following Drug Trial Setbacks
After recent costly clinical trial failures, a major Novartis shareholder is calling for a board shake-up to improve the company's acquisition strategy.
Oncolytics Biotech Reports Positive Pelareorep Data in Colorectal Cancer
Oncolytics Biotech announced positive preclinical results for pelareorep combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
1
2
3
4
5
6
7
8
